If you listen to drugmakers talk, the world diabetes market is fraught with peril. Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition, while Sanofi ($SNY) says its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which kicked off one piece of a huge production buildup on Wednesday. All told, the expansion will add more than 1,200 jobs to the drugmaker. More from FiercePharma